Getting a medicine to where it needs to act
A drug developer has to answer two questions. What can a medicine do, and can it reach the part of the body where it needs to act? BioDelivera is building its company around the second question. [1][2]
The team calls its delivery platform GCV. It is developing the platform for researchers working on medicines that need to reach specific tissues. The company names oncology, autoimmune disease and conditions affecting the central nervous system as research areas. [1][2]
From doctoral research to a company
Twin sisters Ikeda and Orikeda Trashi began working on drug delivery during their doctoral studies at the University of Texas at Dallas. In 2025 they pitched BioDelivera at the university’s Big Idea Competition and won the student track. [2][3][4]
The sisters joined Y Combinator’s Fall 2026 batch. Ikeda serves as CEO. Orikeda leads the science as chief scientific officer and president. [2][3]
Where BioDelivera ranks
A ranked comparison is not yet available for BioDelivera.
The bigger picture
BioDelivera grew out of a question the founders worked on as researchers. They are continuing that work as a company focused on how medicines reach the tissues they are meant to treat. [1][3]
Written by SOTA2 from BioDelivera’s public materials.